Analyst firms · Goldman Sachs · ACAD
Goldman Sachs ACAD price target and rating history
ACADIA Pharmaceuticals Inc. (ACAD) · Health Care
Goldman Sachs rates ACADIA Pharmaceuticals Inc. (ACAD) Sell with a $12 price target, as of its latest action on Nov 4, 2022. It has published 3 rating actions on ACAD since December 2021, including 0 upgrades and 1 downgrade. Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.
- Current rating
- Sell
- Price target
- $12
- Median target, all firms
- $31
- Actions on ACAD
- 3
Goldman Sachs price target on ACAD
Every Goldman Sachs rating on ACAD
- Nov 4, 2022
- Mar 7, 2022
- Dec 8, 2021
How other firms rate ACAD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $23 | Oct 13, 2026 |
| BofA Securities | Buy | $29 | Mar 25, 2026 |
| Wolfe Research | Outperform | $33 | Feb 24, 2026 |
| Mizuho | Outperform | $35 | Feb 23, 2026 |
Questions about Goldman Sachs and ACAD
- What is Goldman Sachs's price target for ACAD?
- Goldman Sachs's latest stated price target for ACADIA Pharmaceuticals Inc. (ACAD) is $12, from its action on Nov 4, 2022.
- What is Goldman Sachs's rating on ACAD?
- Goldman Sachs rates ACAD Sell, a bearish rating, as of Nov 4, 2022.
- When did Goldman Sachs last change its view on ACAD?
- On Nov 4, 2022, Goldman Sachs downgrades to Sell from Neutral, price target $15 to $12.
- How does Goldman Sachs's ACAD target compare with other analysts?
- Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.
More ACAD rating histories
All Goldman Sachs ratingsACAD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.